抗 C1GALT1 自身抗体是头颈部癌症患者的一种新型预后生物标志物。

Anti-C1GALT1 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer.

机构信息

National Taiwan University Cancer Center, Taipei, Taiwan.

Department of Otolaryngology, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.

出版信息

Laryngoscope. 2021 Jan;131(1):E196-E202. doi: 10.1002/lary.28694. Epub 2020 May 19.

DOI:10.1002/lary.28694

PMID:32427353

Abstract

OBJECTIVES

The objective of this study is to determine the value of the anti- glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1) autoantibody as a biomarker for distant metastasis and good response to immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC).

METHODS

In this retrospective study with a median follow-up of 55.7 months, 186 HNSCC patients were enrolled between July 2013 and August 2014. Data were analyzed between April 2018 and November 2019. Titers of autoantibody against the C1GALT1 peptide were measured by ELISA. Student t test, Kaplan-Meier analysis, and univariate and multivariate Cox proportional hazard models were used to evaluate the association of anti-C1GALT1 autoantibody titer with clinicopathologic factors, survival, and response to immunotherapy.

RESULTS

Our results showed that high levels of the anti-C1GALT1 autoantibody is an independent marker for distant metastasis and poor disease-specific survivals in HNSCC patients. In 19 recurrent or metastatic (R/M) HNSCC patients who have received nivolumab or pembrolizumab, higher autoantibody titers are associated with a better treatment response.

CONCLUSION

We propose that the anti-C1GALT1 autoantibody can serve as a novel biomarker for distant metastasis in HNSCC patients. It is also useful in individualized medicine for R/M HNSCC patients who are considering immunotherapy.

LEVEL OF EVIDENCE

IV Laryngoscope, 131:E196-E202, 2021.

摘要

目的

本研究旨在确定抗糖蛋白-N-乙酰半乳糖胺 3-β-半乳糖基转移酶 1（C1GALT1）自身抗体作为头颈部鳞状细胞癌（HNSCC）患者远处转移和对免疫检查点抑制剂良好反应的生物标志物的价值。

方法

在这项中位随访时间为 55.7 个月的回顾性研究中，于 2013 年 7 月至 2014 年 8 月期间招募了 186 例 HNSCC 患者。数据分析于 2018 年 4 月至 2019 年 11 月进行。通过 ELISA 测量针对 C1GALT1 肽的自身抗体滴度。采用学生 t 检验、Kaplan-Meier 分析以及单变量和多变量 Cox 比例风险模型来评估抗 C1GALT1 自身抗体滴度与临床病理因素、生存和对免疫治疗的反应之间的关联。